\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesThe European Commission has announced the opening of further calls with in total 8 call topics under the Digital Europe programme. Calls are expected to open on 4 July 2024.
This short info session aims to provide information on the context and content of the programme and these new call topics, requirements to participate in the programme and the support NCP Flanders can give to interested stakeholders.
Preliminary programme
10.00 - 10.05 Introduction to Digital Europe
10.05 - 10.25 Upcoming calls
10.25 – 10.40 Participation in Digital Europe: requirements, benefits and information sources
10.40 – 10.45 NCP Flanders Support
10.45 - 11.00 Q&A
Targeted public: stakeholders located in Flanders.
Language: the event will be held in English.
Registration: participation is free but registration is required via this link. The log-in instructions for the session will be send the last working day before the event.
This info session will be recorded and made available for registered users of the NCP Flanders website. NCPs reserve the right to decline any registration.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.